Form 4: Aprea Therapeutics Director Rifat Pamukcu Receives Significant Equity Grants

Aprea Therapeutics, Inc. Director Rifat Pamukcu was granted 1,045 restricted stock units and 4,185 stock options, aligning his interests with shareholders.

Summary

• Rifat Pamukcu, a Director of Aprea Therapeutics, Inc. (APRE), was granted equity compensation on June 5, 2025.
• The compensation includes 1,045 restricted stock units (RSUs) and 4,185 stock options.
• The RSUs were granted at a price of $0.00 and will vest on June 5, 2026.
• The stock options have an exercise price of $1.81 per share, vest on June 5, 2026, and expire on June 5, 2035.
• Both the RSUs and options are subject to Mr. Pamukcu's continued service on the board of directors through the applicable vesting date.
• Following these transactions, Mr. Pamukcu directly owns 5,446 shares of common stock and indirectly owns 14,108 shares through ZNZ Holdings LLC, in addition to 4,185 stock options.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal, indicating alignment of interests and continued commitment to the company's long-term success. It's a routine compensation event but reinforces confidence.

Positives

• The grant of restricted stock units and stock options to Director Rifat Pamukcu aligns his interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule, tied to continued service, indicates a commitment from the director to the company's future.

Negatives

• No negative aspects were identified in this Form 4 filing.

Risks

• The vesting of the granted equity is contingent upon the director's continued service on the board, meaning the benefits could be forfeited if service ceases before the vesting date.

Future Outlook

The equity grants are designed to align the director's long-term interests with the company's performance, with vesting contingent on continued service through June 5, 2026.

Management Comments

• The filing indicates that the grants are subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

Industry Context

This Form 4 filing is a standard disclosure of insider equity compensation, a common practice across industries to incentivize and retain key personnel by aligning their financial interests with company performance.

Comparison to Industry Standards

• Equity grants to directors, including restricted stock units and stock options, are a standard component of compensation packages in the biotechnology and pharmaceutical industries, similar to practices observed at companies like BioNTech SE or Moderna, Inc., aiming to foster long-term commitment and performance alignment.
• The specific values and vesting schedules are typical for non-executive director compensation, reflecting a balance between immediate reward and future performance incentives.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of a director's financial interests with the company's long-term performance, potentially leading to more focused decision-making.
• Employees: Indirectly positive as strong governance and aligned leadership can contribute to overall company stability and success.

Next Steps

• Vesting of 1,045 restricted stock units on June 5, 2026, subject to continued board service.
• Vesting of 4,185 stock options on June 5, 2026, subject to continued board service.
• Potential exercise of stock options by June 5, 2035.

Key Dates

Keywords

Aprea Therapeutics, APRE, Form 4, Insider Trading, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership